Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$40.46 USD

40.46
655,511

-0.71 (-1.72%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $40.46 0.00 (0.00%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings Expected to Decline

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rimmi Singhi headshot

4 Toxic Stocks That May Stress You Out Amid Market Turmoil

by Rimmi Singhi

Just like identifying promising stocks, detecting toxic stocks and dumping them at the right time are crucial to safeguarding one's portfolio from big losses.

Zacks.com featured highlights InnovAge Holding, Spirit AeroSystems Holdings, Tandem Diabetes Care and HCI Group

by Zacks Equity Research

InnovAge Holding, Spirit AeroSystems Holdings, Tandem Diabetes Care and HCI Group have been highlighted in this Screen of The Week article.

Rimmi Singhi headshot

4 Toxic Stocks That May Risk Your Peace and Prosperity

by Rimmi Singhi

Stocks like INVV, SPR, TNDM and HCI could prove hazardous for your portfolio. So, it's best to dump these toxic stocks, especially amid the prevailing market mayhem.

Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues

by Zacks Equity Research

Factoring in the pandemic and competitive pressure as well as evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) slashes full-year guidance.

Rimmi Singhi headshot

Distance Yourself From These 4 Toxic Stocks to Ward Off Losses

by Rimmi Singhi

It's time to cut ties with toxic stocks including CNK, LVS, TNDM and HCI to safeguard your portfolio.

Zacks.com featured highlights include Heska, Tandem Diabetes Care, Credit Suisse Group, Zalando SE and Las Vegas Sands

by Zacks Equity Research

Heska, Tandem Diabetes Care, Credit Suisse Group, Zalando SE and Las Vegas Sands are part of Zacks Screen of the Week article.

Rimmi Singhi headshot

5 Toxic Stocks That May Prove Hazardous for Your Portfolio

by Rimmi Singhi

Toxic companies are characterized by huge debt pile and are vulnerable to external shocks. Accurately identifying such stocks and getting rid of them at the right time can protect your portfolio. CS, LVS, HSKA, TNDM and ZLNDY are five such stocks.

Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut

by Zacks Equity Research

Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.

Implied Volatility Surging for Tandem Diabetes Care (TNDM) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Tandem Diabetes Care (TNDM) stock based on the movements in the options market lately.

Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes

by Zacks Equity Research

Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.

CVRx (CVRX) Soars 5.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails

by Zacks Equity Research

Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.

Here's Why Investors Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.

Tandem Diabetes Care, Inc. (TNDM) Soars 6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Tandem Diabetes (TNDM) Posts Positive Control-IQ Study Data

by Zacks Equity Research

Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.

Why Is Tandem Diabetes Care, Inc. (TNDM) Down 16.3% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes (TNDM) Pump Shipment Recovers, Price Issue Ails

by Zacks Equity Research

Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.

Tandem Diabetes (TNDM) Q1 Earnings Lag Estimates, Sales View Up

by Zacks Equity Research

Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.

Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of 13.04% and 9.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Is Tandem Diabetes Care, Inc. (TNDM) Up 4.5% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.

Tandem Diabetes Care, Inc. (TNDM) Q4 Earnings Lag Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -20% and 6.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.

Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.